ERBB2 and breast carcinoma: To date, the application of UCNPconjugates with different breast cancer cell lines have demonstratedexcellent results with highly specific detection of the HER2 biomarker,yielding a 50-fold improvement in signal-to-noise ratio as compared toconventional fluorescent labeling under the same experimental conditions[39].